Exon 19 deletion association with progression-free survival compared to L858R mutation at exon 21 in treatment with first-line EGFR-TKIs: A meta-analysis of subgroup data from eight phase III randomized controlled trials
Journal of Clinical Oncology, 2017.
8107 Background: The superior efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) compared with cytotoxic chemotherapy in patients harboring sensitive EGFR mutations has been extensively proved by a well-known series of eight phase III randomized controlled trials (RCT). However, the question of whether the...More
Full Text (Upload PDF)